Literature DB >> 16134944

Pharmacophore-guided drug discovery investigations leading to bioactive 5-aminotetrahydropyrazolopyridines. Implications for the binding mode of heterocyclic dopamine D3 receptor agonists.

Jan Elsner1, Frank Boeckler, Frank W Heinemann, Harald Hübner, Peter Gmeiner.   

Abstract

Taking advantage of a 3D-QSAR based pharmacophore hypothesis, synthesis and biological evaluation of dopaminergic 5-aminotetrahydropyrazolo[1,5-a]pyridines are described. The data displayed substantial and selective D3 receptor affinity for the heterocyclic test compound (+/-)-1 when the enantiomer (S)-1 turned out to be responsible for the D3 binding (K(i) (high) = 4.0 nM). (S)-1 exhibited binding affinity and ligand efficacy comparable to those of our previously described D3 agonist FAUC 54, when subtype selectivity could be significantly improved. The results indicate that the sp(2) nitrogens of the pyrazole and thiazole rings of the dopaminergics (S)-1 and pramipexole, respectively, are pharmacophoric elements of major importance. To provide putative explanations for the high affinity of (S)-1, computational studies were performed employing an active state D3 model.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16134944     DOI: 10.1021/jm0503805

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  7 in total

1.  Engineering a GPCR-ligand pair that simulates the activation of D(2L) by Dopamine.

Authors:  Nuska Tschammer; Miriam Dörfler; Harald Hübner; Peter Gmeiner
Journal:  ACS Chem Neurosci       Date:  2009-09-24       Impact factor: 4.418

2.  Investigation of various N-heterocyclic substituted piperazine versions of 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-2-ol: effect on affinity and selectivity for dopamine D3 receptor.

Authors:  Dennis A Brown; Manoj Mishra; Suhong Zhang; Swati Biswas; Ingrid Parrington; Tamara Antonio; Maarten E A Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2009-04-19       Impact factor: 3.641

3.  Modification of agonist binding moiety in hybrid derivative 5/7-{[2-(4-aryl-piperazin-1-yl)-ethyl]-propyl-amino}-5,6,7,8-tetrahydro-naphthalen-1-ol/-2-amino versions: impact on functional activity and selectivity for dopamine D2/D3 receptors.

Authors:  Bhaskar Gopishetty; Suhong Zhang; Prashant S Kharkar; Tamara Antonio; Maarten Reith; Aloke K Dutta
Journal:  Bioorg Med Chem       Date:  2013-04-01       Impact factor: 3.641

Review 4.  Dopamine and Dopamine-Related Ligands Can Bind Not Only to Dopamine Receptors.

Authors:  Jaromir Myslivecek
Journal:  Life (Basel)       Date:  2022-04-19

5.  Understanding the Structural Requirements of Hybrid (S)-6-((2-(4-Phenylpiperazin-1-yl)ethyl)(propyl)amino)-5,6,7,8-tetrahydronaphthalen-1-ol and its Analogs as D2/D3 Receptor Ligands: A Three-Dimensional Quantitative Structure-Activity Relationship (3D QSAR) Investigation.

Authors:  Gyan Modi; Horrick Sharma; Prashant S Kharkar; Aloke K Dutta
Journal:  Medchemcomm       Date:  2014-09-01       Impact factor: 3.597

6.  Identification of Novel Dopamine D2 Receptor Ligands-A Combined In Silico/In Vitro Approach.

Authors:  Lukas Zell; Constanze Lainer; Jakub Kollár; Veronika Temml; Daniela Schuster
Journal:  Molecules       Date:  2022-07-11       Impact factor: 4.927

7.  Structural modifications of neuroprotective anti-Parkinsonian (-)-N6-(2-(4-(biphenyl-4-yl)piperazin-1-yl)-ethyl)-N6-propyl-4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine (D-264): an effort toward the improvement of in vivo efficacy of the parent molecule.

Authors:  Gyan Modi; Tamara Antonio; Maarten Reith; Aloke Dutta
Journal:  J Med Chem       Date:  2014-02-12       Impact factor: 7.446

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.